FDA
-
-
-
-
-
-
-
Raymond James Starts Phathom Pharmaceuticals (PHAT) at Strong Buy, PT $28
-
-
-
-
-
-
-
Phathom Pharmaceuticals (PHAT) Announces FDA Correction to Orange Book Listing
-
-
-
-
-
-
-
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
-
-
-
-
-
-
-
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)
-
-
-
-
-
-
-
Phathom Pharmaceuticals Inc. (PHAT) Announces FDA Approval of VOQUEZNA
-
-
-
-
-
-
-
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
-
324,067 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

